Clinical trial
Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32
NCT00116012 · ARCA Biopharma, Inc., Industry · Completed
Key facts
| NCT number | NCT00116012 |
|---|---|
| Title | Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32 |
| Official title | A Randomized, Double-Blind Placebo-Controlled Study to Assess the Safety of Factor VIIa/Tissue Factor Inhibitor, Recombinant Nematode Anticoagulant Protein c2 (rNAPc2), in Subjects With Non-ST-Elevation Acute Coronary Syndromes - ANTHEM (Anticoagulation With rNAPc2 to Help Eliminate MACE)/TIMI 32… |
| Lead sponsor | ARCA Biopharma, Inc., Industry |
| Collaborators | The TIMI Study Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Disease |
| Intervention type | Drug |
| Interventions | rNAPc2 |
| Enrollment | 300 |
| Start date | Jun 1, 2005 |
| First posted | Jun 27, 2005 |
| Last update posted | Nov 29, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: